Kapruvia® approved by European Commission for the treatment

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe...

Related Keywords

Norway ,Iceland ,Liechtenstein ,Switzerland ,Swiss ,Vifor Pharma ,Iris Francesconi ,Klaus Henning Jensen ,Annie Spinetta ,Nathalie Ponnier ,Joana Goncalves ,Swiss Stock Exchange ,European Commission ,Drug Administration ,Global Head Corporate Communications ,Swiss Exchange ,International Journal Of Nephrology ,Nasdaq ,Exchange Commission ,Cara Therapeutics Inc ,Vifor Pharma Group ,European Union ,National Registry Study ,Fresenius Medical Care ,Vifor Fresenius Medical Care Renal Pharma ,Cara Therapeutics ,Chief Medical Officer ,Pharma Group ,Sanifit Therapeutics ,Registry Study ,Private Securities Litigation Reform Act ,Annual Report ,Dialysis Outcomes ,Practice Patterns ,Nephrol Dial ,International Journal ,Patient Reported Outcomes ,Uremic Pruritus ,Clinj Am Soc ,Nasdaq Cara ,Nc ,